auto-fix: address review feedback on 2021-02-00-mckinsey-facility-to-home-265-billion-shift.md

- Fixed based on eval review comments
- Quality gate pass 3 (fix-from-feedback)

Pentagon-Agent: Vida <HEADLESS>

domains/health/265-billion-medicare-care-could-shift-from-facilities-to-home-by-2025-requiring-3-4x-capacity-increase.md

@@ -1,25 +1,33 @@
 ---
 type: claim
 domain: health
-description: "McKinsey projected $265B in Medicare care could shift from facilities to home by 2025, but the 2025 deadline has passed without documented validation of the projection"
+description: "McKinsey 2021 projection that $265B in Medicare care could shift from facilities to home by 2025, requiring 3-4x capacity increase over 2020 baseline. The 2025 deadline has passed without comprehensive validation data."
 confidence: experimental
 source: "McKinsey & Company, From Facility to Home (Feb 2021)"
 created: 2026-03-11
 secondary_domains: []
+challenged_by: []
 ---
 
-# McKinsey projected $265B in Medicare care could shift from facilities to home by 2025, requiring 3-4x capacity increase over 2020 baseline
+# McKinsey projected $265B in Medicare care could shift from facilities to home, but the 2025 deadline has passed without documented validation
 
 In February 2021, McKinsey projected that up to $265 billion in care services—representing 25% of total Medicare cost of care—could shift from facilities to home by 2025. This projection assumed a 3-4x increase versus the 2020 baseline of approximately $65 billion in home-based care.
 
-## Status: Projection Timeline Has Passed
+## Status: Projection Timeline Has Passed — Now a Testable Historical Claim
 
 The 2025 deadline specified in the original McKinsey projection has now passed (we are in March 2026). This claim should be evaluated as a **historical projection** rather than a forward forecast. Actual data on facility-to-home care migration through 2025 would confirm or falsify this projection. As of this extraction date, we lack comprehensive 2025 data validating whether the projected shift occurred.
 
+**Key question for KB validation:** Did Medicare facility-to-home care migration reach $265B by end of 2025, or did it fall short? Current evidence status: unverified.
+
 ## Structural Insight: Capacity Boundary Problem
 
 The extractable insight is not the dollar figure itself but the **capacity boundary problem**: the gap between current ($65B) and projected ($265B) home care capacity mirrors the value-based care payment transition gap. Both face the same constraint: enabling infrastructure must scale faster than economic incentive alone can drive it.
 
+This structural parallel connects to the broader attractor state thesis — the facility-to-home shift is a necessary component of prevention-first care delivery, but it requires simultaneous scaling of three independent systems:
+1. Technology infrastructure (RPM, monitoring, AI middleware)
+2. Workforce capacity (home health providers)
+3. Regulatory/payment enablement (reimbursement, licensure)
+
 ## Services Addressable at Home
 
 **Already feasible for home delivery:** Primary care, outpatient-specialist consults, hospice, outpatient behavioral health
@@ -34,7 +42,7 @@ The extractable insight is not the dollar figure itself but the **capacity bound
 
 ## Enabling Technology Stack (Projected)
 
-The projection assumes rapid scaling of the technology layer that makes home-based care safe:
+The projection assumes rapid scaling of the technology layer that makes home-based care safe and economically viable:
 
 - Remote patient monitoring market: $29B → $138B (2024-2033), 19% CAGR
 - AI in RPM: $2B → $8.4B (2024-2030), 27.5% CAGR
@@ -60,6 +68,15 @@ The projection rests on three simultaneous transitions:
 
 All three must proceed without friction for the projection to hold. Actual 2025-2026 data would show whether these assumptions held.
 
+## Confidence Calibration: Experimental
+
+Rated `experimental` rather than `likely` because:
+
+1. **Single-source projection** — McKinsey 2021 report is the primary source; no independent validation of the $265B figure from other research firms
+2. **Timeline now testable** — The 2025 deadline has passed. Validation requires actual CMS/Medicare data on care site migration through 2025, which is not yet available in this extraction
+3. **Capacity assumptions untested** — The 3-4x workforce scaling assumption has not been validated; home health labor constraints may prevent the projected shift
+4. **Technology scaling risk** — RPM market projections ($29B→$138B) are from market research firms, not validated adoption data
+
 ---
 
 Relevant Notes:

domains/health/home-based-care-economics-show-19-52-percent-cost-reduction-across-multiple-care-settings.md

@@ -1,10 +1,11 @@
 ---
 type: claim
 domain: health
-description: "Home-based care achieves 19-52% cost reduction versus facility care in specific settings, but integrated care models like PACE show cost redistribution rather than total cost reduction"
+description: "Home-based care achieves 19-52% cost reduction versus facility care in specific acute and chronic settings, but integrated care models like PACE show cost redistribution rather than total cost reduction"
 confidence: experimental
-source: "Johns Hopkins hospital-at-home program; systematic review of heart failure home care (cited in McKinsey 2021); ASPE PACE evaluation"
+source: "Johns Hopkins hospital-at-home program (Leff et al.); systematic review of heart failure home care (cited in McKinsey 2021); ASPE PACE evaluation"
 created: 2026-03-11
+secondary_domains: []
 challenged_by: ["pace-restructures-costs-from-acute-to-chronic-spending-without-reducing-total-expenditure-challenging-prevention-saves-money-narrative.md", "pace-demonstrates-integrated-care-averts-institutionalization-through-community-based-delivery-not-cost-reduction.md"]
 ---
 
@@ -14,7 +15,7 @@ Empirical evidence from specific care settings demonstrates cost reduction for h
 
 **Hospital-at-home (acute):** Johns Hopkins program shows 19-30% cost savings versus traditional in-hospital care for conditions that can be safely managed at home with appropriate monitoring and clinical support. (Leff et al., primary source)
 
-**Chronic disease management:** A systematic review of home care for heart failure patients demonstrates 52% lower costs compared to facility-based management. *(Note: This figure is cited second-hand through McKinsey 2021; primary source not directly verified)*
+**Chronic disease management:** A systematic review of home care for heart failure patients demonstrates 52% lower costs compared to facility-based management. *(Note: This figure is cited second-hand through McKinsey 2021; primary source not directly verified. This is the most dramatic number in the claim and represents a data provenance concern.)*
 
 **Remote monitoring-enabled care:** RPM for chronic disease management shows significant reduction in avoidable hospitalizations, which drive the majority of Medicare acute care costs.
 
@@ -36,16 +37,23 @@ This suggests that the 'cost savings' narrative may be misleading. Home-based ca
 
 The McKinsey analysis explicitly states the facility-to-home shift is achievable "without reduction in quality or access." This is a material claim because cost reduction + quality preservation = structural advantage, not a trade-off. The Johns Hopkins and heart failure evidence both document cost reduction without quality degradation. However, the PACE data suggests that when fully integrated care is implemented at scale, quality improvements (institutionalization avoidance, mortality reduction) may be the primary value driver rather than cost reduction.
 
-## Confidence Calibration
+## Confidence Calibration: Experimental
 
 This claim is rated `experimental` rather than `likely` because:
 
-1. **Second-hand evidence:** The 52% heart failure figure is cited only through McKinsey, not from the primary source. This is the most dramatic number in the claim and represents a data provenance concern.
+1. **Second-hand evidence on the 52% figure:** The 52% heart failure cost reduction is cited only through McKinsey 2021, not from the primary source. This is the most dramatic number in the claim and represents a data provenance concern. The Johns Hopkins 19-30% figure is more defensible (Leff et al. published directly), but the 52% figure weakens the overall evidence base.
-2. **Limited sample:** Evidence comes from two independent sources (Johns Hopkins + systematic review) rather than a broader evidence base.
-3. **Direct contradiction:** The PACE data directly challenges the cost-reduction narrative. Integrated care models show cost redistribution, not reduction.
-4. **Scale-up risk:** Cost advantage may not persist if home care capacity becomes constrained or if full integration (like PACE) is implemented.
 
-The claim should be reframed: home-based care achieves cost reduction in specific settings and conditions, but integrated care models suggest the primary value may be quality/outcome improvements rather than total cost reduction.
+2. **Limited sample size:** Evidence comes from two independent sources (Johns Hopkins + systematic review) rather than a broader evidence base. Two data points do not establish a pattern across "multiple care settings" as the title claims.
+
+3. **Direct contradiction from PACE:** The PACE data directly challenges the cost-reduction narrative. Integrated care models show cost redistribution, not reduction. This is not a minor caveat—it's a fundamental tension with the claim's core proposition.
+
+4. **Scale-up risk:** Cost advantage may not persist if home care capacity becomes constrained or if full integration (like PACE) is implemented. The economics of home-based care may depend on it remaining a marginal delivery model rather than becoming the default.
+
+5. **Specificity of settings:** The cost reduction is documented in specific conditions (heart failure, post-acute care, primary care) and specific programs (Johns Hopkins). Generalization to "across multiple care settings" is an inference, not a direct finding.
+
+## Reframed Proposition
+
+The claim should be understood as: **Home-based care achieves cost reduction in specific acute and chronic care settings (Johns Hopkins hospital-at-home, heart failure management), but integrated care models like PACE suggest the primary value may be quality/outcome improvements (institutionalization avoidance) rather than total cost reduction.**
 
 ---